breast cancer
British oncologists have found a way to treat triple-negative breast cancer, which is one of the most dangerous types of cancer.
In a report published by the Russian newspaper "Gazeta", the author, Ala Salkova, indicated that relying on immunotherapy and chemotherapy at the same time increases the chances of eliminating one of the most dangerous and aggressive types of breast cancer that affects women.
The author said that experts from Queen Mary University in London presented the results of their research during the European Society of Gynecological Oncology conference in Barcelona.
And experts say that breast cancer treatment is often through hormone therapy. But cancer cells usually carry receptors for the hormone progesterone and estrogen, which stimulate cells to divide, which contributes to tumor development. They also showed that the use of drugs that block hormones, can prevent tumor growth.
Negative triple breast cancer
But between 12 and 20% of women with triple-negative breast cancer, their tumors lack estrogen, progesterone, or epidermal growth factor.
In most cases of passive triple breast cancer, chemotherapy is used, then surgery to get rid of passive triple breast cancer. In the event that not all cancerous tissue is removed, the tumor will reappear in 40 or 50% of cases within three years.
The high rate of survival of women
Between March 2017 and September 2018, and in 128 cities in 21 countries, approximately 1,174 women with triple-negative breast cancer underwent chemotherapy and then the tumor removal process. Of these, 784 women received an immunological treatment for cancer known as "pimrolisumab" - which is also recommended for skin and lung cancer treatment - before and after surgery, while the others received a placebo.
Research has found that the rate of relapses among women who receive "bprolizumab" is much lower than the rate of relapses among women who received a placebo.
Also, the side effects of chemotherapy and the complications attributable to immunotherapy were recorded at 42% of the participants who received "bimolizumab", compared to 21% in those who received the placebo. The researchers also noted a higher survival rate among women who received immunotherapy.
A treatment that saves thousands of lives
According to researcher at Queen Mary University, Peter Schmid, "Triple negative breast cancer is one of the most dangerous types of cancer and we are looking for the best options for its treatment. Also, these early results indicate that adding immunotherapy to chemotherapy reduces the possibility of this disease appearing again."
Although the results are still preliminary, researchers have high hopes that this treatment can save thousands of lives. This is only the first stage of the study. Scientists expect that more research and depth will give them more reasons to recommend immunotherapy as an effective way to combat triple-negative breast cancer.
If the results are confirmed, then a combination of immunotherapy and chemotherapy may become the new standard for treatment. Earlier, American scientists proposed a new way to treat breast cancer, using a device specifically designed to freeze cancer cells with carbon dioxide.
The author emphasized that the new treatment can save thousands of lives, especially as it does not require surgical intervention, anesthesia, or medication. And the treatment devised by American researchers is capable of killing up to 80% of cancer cells.
